Michael Rome, Ph.D.

Michael Rome, Ph.D.
Managing Director, Foresite Capital

Dr. Rome has been a director since July 2020. Dr. Rome has worked with Foresite Capital since 2016 and is active in the firm’s private and public market investments. Dr. Rome is a board director at Kinnate Biopharma, Pharvaris and Remix Therapeutics with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, PACT Pharma, and Nurix Therapeutics. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies.

Dr. Rome received his Ph.D. in Biochemistry from Caltech as an NSF graduate research fellow, and his B.S. in Molecular, Cell and Developmental Biology from UCLA. Dr. Rome has more than 12 years of experience as a research scientist and has authored numerous publications in biomedical research journals.